BriaCell Therapeutics Corp. (BCTX)

BriaCell Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is August - July.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2026	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Cash & Equivalents	6.88	10.49	0.86	21.25	41.04	57.27
Short-Term Investments	15.92	7.37	-	-	-	-
Cash & Short-Term Investments	22.8	17.87	0.86	21.25	41.04	57.27
Cash Growth	83.02%	1972.44%	-95.94%	-48.22%	-28.34%	269412.38%
Other Receivables	-	-	0.74	-	0.02	0.01
Receivables	-	-	0.74	-	0.02	0.01
Prepaid Expenses	2.59	2.06	2.06	5.7	1.28	0.52
Total Current Assets	25.39	19.93	3.65	26.95	42.35	57.8
Property, Plant & Equipment	0.35	0.3	0.39	-	-	-
Long-Term Investments	0.75	0.52	0.42	0	0	0
Other Intangible Assets	0.17	0.18	0.2	0.22	0.23	0.25
Other Long-Term Assets	0.41	0.72	1.21	-	-	-
Total Assets	27.07	21.65	5.87	27.16	42.58	58.04

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2026	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Accounts Payable	2.17	3.28	7.17	1.12	0.46	0.21
Accrued Expenses	1.42	0.69	0.29	0.68	0.48	0.34
Total Current Liabilities	3.59	3.98	7.46	1.8	0.94	0.56
Long-Term Debt	-	-	-	-	-	0.03
Other Long-Term Liabilities	0.07	0.34	1.1	29.14	31.31	29.79
Total Liabilities	3.66	4.32	8.56	30.94	32.25	30.37

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2026	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Common Stock	117.12	101.74	72.17	69.59	65.59	54.77
Additional Paid-In Capital	-	-	-	-	-	2.18
Retained Earnings	-134.34	-111.76	-85.44	-80.65	-60.35	-29.14
Comprehensive Income & Other	41.28	27.9	10.89	7.28	5.09	-0.14
Total Common Equity	24.06	17.88	-2.38	-3.78	10.33	27.67
Minority Interest	-0.65	-0.55	-0.3	-	-	-
Shareholders' Equity	23.41	17.33	-2.68	-3.78	10.33	27.67
Total Liabilities & Equity	27.07	21.65	5.87	27.16	42.58	58.04

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2026	Jul 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022	Jul 31, 2021
Total Debt	-	-	-	-	-	0.03
Net Cash (Debt)	22.8	17.87	0.86	21.25	41.04	57.24
Net Cash Growth	83.02%	1972.44%	-95.94%	-48.22%	-28.30%	-
Net Cash Per Share	7.18	42.23	7.86	204.08	397.33	1899.79
Filing Date Shares Outstanding	8.7	1.88	0.12	0.11	0.1	0.1
Total Common Shares Outstanding	7.25	1.88	0.12	0.11	0.1	0.1
Working Capital	21.8	15.95	-3.81	25.15	41.41	57.24
Book Value Per Share	3.32	9.49	-19.54	-35.45	99.84	271.83
Tangible Book Value	23.88	17.7	-2.58	-3.99	10.1	27.43
Tangible Book Value Per Share	3.29	9.39	-21.18	-37.47	97.61	269.42
Machinery	-	0.46	0.46	-	-	-

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Mar 10, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 31, 2026

Data Sources Report a data error